Merck Sharp & Dohme Launches Januvia In China To Join Race In Second-largest Diabetes Market
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Having received approval from China's State FDA for Januvia (sitagliptin), Merck Sharp & Dohme announced March 21 that it has launched the dipeptidyl peptidase-4 inhibitor for Type 2 diabetes and joined the race to compete in China's $300 million oral diabetes drug market
You may also be interested in...
Emerging Markets Earnings Roundup: Merck And Novo Nordisk
In this earnings round up, we zoom in on Merck and Novo Nordisk’s performance in emerging markets for 2012.
Emerging Markets Earnings Roundup: Merck And Novo Nordisk (Part 5)
In this earnings round up, we zoom in on Merck and Novo Nordisk performance in emerging markets for 2012.
Merck Doubles Down On Diabetes In China, Launches Janumet
China, home to the world’s largest diabetes population, sees another major product launch as multinationals jockey for position in the DPP-4 space in anticipation of the next NDRL revision.